Lilly Gets U.S. FDA Approval of Jaypirca to Treat MCL

Eli Lilly’s oncology unit Loxo@Lilly received US FDA approval of Jaypirca for the treatment of adult patients with relapsed or refractory mantle cell lymphoma MCL after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase BTK inhibitor.

• The FDA approval is based on data from a subset of patients in the BRUIN Phase 1/2 trial
• “We are pleased to bring a meaningful new therapeutic option to patients with MCL that can reestablish the benefit of targeting the BTK pathway after receiving multiple prior therapies, including a covalent BTK inhibitor,” said Jacob Van Naarden, chief executive officer, ...